The present invention provides novel dihydropyridophthalazinone compounds of Formula (I) as PARP inhibitors, and their pharmaceutically acceptable salts, solvates, hydrates, prodrugs and metabolites thereof, the preparation thereof, and the use of such compounds to treat DNA repair dysregulation diseases and conditions such as cancer. The present provides therapeutic applications for the treatment of stroke, myocardial infarction, neurodegenerative diseases, ovarian cancer, breast cancer, prostate cancer, lung cancer, colorectal cancer, and melanoma.
